Cancer Patients Receiving Myelosuppressive Chemotherapy: Recombinant G-CSF is indicated to decrease the incidence of infection, as manifested by febrile neutropenia. In-patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever. A complete blood count (CBC) and platelet count should be obtained prior to chemotherapy, and twice per week during Recombinant G-CSF therapy to avoid leukocytosis and to monitor the neutrophil count.
Patients with Acute Myeloid Leukemia Receiving Induction or Consolidation Chemotherapy: Recombinant G-CSF is indicated for reducing the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of adults with AML.
Cancer Patients Receiving Bone Marrow Transplant: Recombinant G-CSF is indicated to reduce the duration of neutropenia and neutropenia-related clinical sequelae, eg, febrile neutropenia, in-patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by marrow transplantation. It is recommended that CBCs and platelet counts be obtained at a minimum of 3 times per week following marrow infusion to monitor the recovery of marrow reconstitution.
Patients Undergoing Peripheral Blood Progenitor Cell Collection and Therapy: Recombinant G-CSF is indicated for the mobilization of hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis. Mobilization allows for the collection of increased numbers of progenitor cells capable of engraftment compared with collection by leukapheresis without mobilization or bone marrow harvest.